FULGENT GENETICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares
FULGENT GENETICS, INC. (FLGT) reported Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares of 0 shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares · last filed 2026-02-27
- FULGENT GENETICS, INC. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2025 was 0.00 shares.
- FULGENT GENETICS, INC. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2024 was 0.00 shares.
- FULGENT GENETICS, INC. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- FULGENT GENETICS, INC. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2022 was 55.00K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 12 month |
|---|---|
| 2025-12-31 | 0.00 shares 10-K · filed 2026-02-27 |
| 2024-12-31 | 0.00 shares 10-K · filed 2026-02-27 |
| 2023-12-31 | 0.00 shares 10-K · filed 2026-02-27 |
| 2022-12-31 | 55.00K shares 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |